Royalty Pharma plc Debt Securities, Available-for-sale
Royalty Pharma plc (RPRX) had Debt Securities, Available-for-sale of $428.70 million as of 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-02-11
- 2025-12-31: Debt Securities, Available-for-sale $428.70M.
- 2025-09-30: Debt Securities, Available-for-sale $307.50M.
- 2025-06-30: Debt Securities, Available-for-sale $257.90M.
- 2025-03-31: Debt Securities, Available-for-sale $213.20M.
| Period end | Debt Securities, Available-for-sale | Debt Securities, Available-for-sale as first filed |
|---|---|---|
| 2025-12-31 | $428.70M 10-K · filed 2026-02-11 | |
| 2025-09-30 | $307.50M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $257.90M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $213.20M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $739.62M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $701.20M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $646.40M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $499.48M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $454.50M 10-K · filed 2025-02-12 | |
| 2023-09-30 | $347.60M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $340.30M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $257.40M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $225.10M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $739.25M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $383.00M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $304.40M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $270.40M 10-K · filed 2023-02-15 | |
| 2021-09-30 | $255.70M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $271.20M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $249.20M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $233.00M 10-K · filed 2022-02-15 | $214.40M 10-K · filed 2021-02-24 |
| 2020-09-30 | $198.53M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $190.95M 10-Q · filed 2020-08-12 | |
| 2019-12-31 | $131.28M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |